Literature DB >> 6403616

Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

J L Pace, S W Russell, B A Torres, H M Johnson, P W Gray.   

Abstract

Mouse macrophages become activated to kill tumor cells by traversing a series of steps (1-3). The first of these does not cause the expression of cytolytic activity; instead, it primes macrophages to respond to a second signal(s) that then triggers the onset of killing (4-7). The mediator that is responsible for priming is contained, along with other lymphokines, in the culture supernatants of concanavalin A-stimulated spleen cells (5-7) cloned T lymphocytes (8), or some T cell hybridomas (9). Close association has been noted between macrophage priming activity and antiviral activity that is attributable to gamma interferon (10-12). However, unequivocal evidence that the two activities are products of the same molecule has not been available. We now how conclusively by using mouse gamma interferon (MulFN-gamma)3 produced by recombinant DNA technology that, in addition to antiviral activity, this lymphokine has the capacity to induce the priming step in the process of macrophage activation for tumor cell killing.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  105 in total

1.  Role of intracellular calcium as a priming signal for the induction of nitric oxide synthesis in murine peritoneal macrophages.

Authors:  Y C Park; C D Jun; H S Kang; H D Kim; H M Kim; H T Chung
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Synergistic induction of cytotoxicity in macrophages by murine interferon-gamma and biological response modifiers derived from microorganisms.

Authors:  S Nagao; K Sato; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro.

Authors:  M Khor; D B Lowrie; D A Mitchison
Journal:  Br J Exp Pathol       Date:  1986-10

4.  Staphylococcal exotoxins stimulate nitric oxide-dependent murine macrophage tumoricidal activity.

Authors:  D J Fast; B J Shannon; M J Herriott; M J Kennedy; J A Rummage; R W Leu
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

5.  Modulation of monocyte complement synthesis by interferons.

Authors:  A O Hamilton; L Jones; L Morrison; K Whaley
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

6.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

7.  A distal locus element mediates IFN-γ priming of lipopolysaccharide-stimulated TNF gene expression.

Authors:  Nancy A Chow; Luke D Jasenosky; Anne E Goldfeld
Journal:  Cell Rep       Date:  2014-12-04       Impact factor: 9.423

8.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  Effect of mouse lymphokines and cloned mouse interferon-gamma on the interaction of Rickettsia prowazekii with mouse macrophage-like RAW264.7 cells.

Authors:  J Turco; H H Winkler
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

10.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

Authors:  Y Watanabe; K Kuribayashi; S Miyatake; K Nishihara; E Nakayama; T Taniyama; T Sakata
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.